Selected research
Industry Research
Bi-Specific Antibodies Therapy Industry Research Report 2026
Market perspective
The global Bi-Specific Antibodies Therapy market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Bi-Specific Antibodies Therapy market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Bi-Specific Antibodies Therapy market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Bi-Specific Antibodies Therapy market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Bi-Specific Antibodies Therapy include Alphamab Co. Ltd, Genmab, Lindis Biotech, MacroGenics, Inc, AstraZeneca, AbbVie, Amgen, Pfizer and Akeso, Inc., among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Bi-Specific Antibodies Therapy market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Bi-Specific Antibodies Therapy.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Bi-Specific Antibodies Therapy Market by Company
Alphamab Co. Ltd
Genmab
Lindis Biotech
MacroGenics, Inc
AstraZeneca
AbbVie
Amgen
Pfizer
Akeso, Inc.
Roche
Johnson & Johnson
Sanofi
Bi-Specific Antibodies Therapy Segment by Type
Fragment-Based Antibodies
IgG-Based Antibodies
Bi-Specific Antibodies Therapy Segment by Application
Cancer
Haemophilia
Other Non-Cancer Diseases
Bi-Specific Antibodies Therapy Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bi-Specific Antibodies Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Bi-Specific Antibodies Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bi-Specific Antibodies Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Bi-Specific Antibodies Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Fragment-Based Antibodies
- IgG-Based Antibodies
Applications
- Cancer
- Haemophilia
- Other Non-Cancer Diseases
Companies covered
- Alphamab Co. Ltd
- Genmab
- Lindis Biotech
- MacroGenics, Inc
- AstraZeneca
- AbbVie
- Amgen
- Pfizer
- Akeso, Inc.
- Roche
- Johnson & Johnson
- Sanofi
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Bi-Specific Antibodies Therapy by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Fragment-Based Antibodies
- 2.2.3 IgG-Based Antibodies
- 2.3 Bi-Specific Antibodies Therapy by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Cancer
- 2.3.3 Haemophilia
- 2.3.4 Other Non-Cancer Diseases
- 2.4 Assumptions and Limitations
3 Bi-Specific Antibodies Therapy Breakdown Data by Type
- 3.1 Global Bi-Specific Antibodies Therapy Historic Market Size by Type (2021-2026)
- 3.2 Global Bi-Specific Antibodies Therapy Forecasted Market Size by Type (2027-2032)
4 Bi-Specific Antibodies Therapy Breakdown Data by Application
- 4.1 Global Bi-Specific Antibodies Therapy Historic Market Size by Application (2021-2026)
- 4.2 Global Bi-Specific Antibodies Therapy Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Bi-Specific Antibodies Therapy Market Perspective (2021-2032)
- 5.2 Global Bi-Specific Antibodies Therapy Growth Trends by Region
- 5.2.1 Global Bi-Specific Antibodies Therapy Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Bi-Specific Antibodies Therapy Historic Market Size by Region (2021-2026)
- 5.2.3 Bi-Specific Antibodies Therapy Forecasted Market Size by Region (2027-2032)
- 5.3 Bi-Specific Antibodies Therapy Market Dynamics
- 5.3.1 Bi-Specific Antibodies Therapy Industry Trends
- 5.3.2 Bi-Specific Antibodies Therapy Market Drivers
- 5.3.3 Bi-Specific Antibodies Therapy Market Challenges
- 5.3.4 Bi-Specific Antibodies Therapy Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Bi-Specific Antibodies Therapy Players by Revenue
- 6.1.1 Global Top Bi-Specific Antibodies Therapy Players by Revenue (2021-2026)
- 6.1.2 Global Bi-Specific Antibodies Therapy Revenue Market Share by Players (2021-2026)
- 6.2 Global Bi-Specific Antibodies Therapy Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Bi-Specific Antibodies Therapy Head Office and Area Served
- 6.4 Global Bi-Specific Antibodies Therapy Players, Product Type & Application
- 6.5 Global Bi-Specific Antibodies Therapy Manufacturers Established Date
- 6.6 Global Bi-Specific Antibodies Therapy Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Bi-Specific Antibodies Therapy Market Size (2021-2032)
- 7.2 North America Bi-Specific Antibodies Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Bi-Specific Antibodies Therapy Market Size by Country (2021-2026)
- 7.4 North America Bi-Specific Antibodies Therapy Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Bi-Specific Antibodies Therapy Market Size (2021-2032)
- 8.2 Europe Bi-Specific Antibodies Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Bi-Specific Antibodies Therapy Market Size by Country (2021-2026)
- 8.4 Europe Bi-Specific Antibodies Therapy Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Bi-Specific Antibodies Therapy Market Size (2021-2032)
- 9.2 Asia-Pacific Bi-Specific Antibodies Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Bi-Specific Antibodies Therapy Market Size (2021-2032)
- 10.2 South America Bi-Specific Antibodies Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Bi-Specific Antibodies Therapy Market Size by Country (2021-2026)
- 10.4 South America Bi-Specific Antibodies Therapy Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Bi-Specific Antibodies Therapy Market Size (2021-2032)
- 11.2 Middle East & Africa Bi-Specific Antibodies Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Alphamab Co. Ltd
- 12.1.1 Alphamab Co. Ltd Company Information
- 12.1.2 Alphamab Co. Ltd Business Overview
- 12.1.3 Alphamab Co. Ltd Revenue in Bi-Specific Antibodies Therapy Business (2021-2026)
- 12.1.4 Alphamab Co. Ltd Bi-Specific Antibodies Therapy Product Portfolio
- 12.1.5 Alphamab Co. Ltd Recent Developments
- 12.2 Genmab
- 12.2.1 Genmab Company Information
- 12.2.2 Genmab Business Overview
- 12.2.3 Genmab Revenue in Bi-Specific Antibodies Therapy Business (2021-2026)
- 12.2.4 Genmab Bi-Specific Antibodies Therapy Product Portfolio
- 12.2.5 Genmab Recent Developments
- 12.3 Lindis Biotech
- 12.3.1 Lindis Biotech Company Information
- 12.3.2 Lindis Biotech Business Overview
- 12.3.3 Lindis Biotech Revenue in Bi-Specific Antibodies Therapy Business (2021-2026)
- 12.3.4 Lindis Biotech Bi-Specific Antibodies Therapy Product Portfolio
- 12.3.5 Lindis Biotech Recent Developments
- 12.4 MacroGenics, Inc
- 12.4.1 MacroGenics, Inc Company Information
- 12.4.2 MacroGenics, Inc Business Overview
- 12.4.3 MacroGenics, Inc Revenue in Bi-Specific Antibodies Therapy Business (2021-2026)
- 12.4.4 MacroGenics, Inc Bi-Specific Antibodies Therapy Product Portfolio
- 12.4.5 MacroGenics, Inc Recent Developments
- 12.5 AstraZeneca
- 12.5.1 AstraZeneca Company Information
- 12.5.2 AstraZeneca Business Overview
- 12.5.3 AstraZeneca Revenue in Bi-Specific Antibodies Therapy Business (2021-2026)
- 12.5.4 AstraZeneca Bi-Specific Antibodies Therapy Product Portfolio
- 12.5.5 AstraZeneca Recent Developments
- 12.6 AbbVie
- 12.6.1 AbbVie Company Information
- 12.6.2 AbbVie Business Overview
- 12.6.3 AbbVie Revenue in Bi-Specific Antibodies Therapy Business (2021-2026)
- 12.6.4 AbbVie Bi-Specific Antibodies Therapy Product Portfolio
- 12.6.5 AbbVie Recent Developments
- 12.7 Amgen
- 12.7.1 Amgen Company Information
- 12.7.2 Amgen Business Overview
- 12.7.3 Amgen Revenue in Bi-Specific Antibodies Therapy Business (2021-2026)
- 12.7.4 Amgen Bi-Specific Antibodies Therapy Product Portfolio
- 12.7.5 Amgen Recent Developments
- 12.8 Pfizer
- 12.8.1 Pfizer Company Information
- 12.8.2 Pfizer Business Overview
- 12.8.3 Pfizer Revenue in Bi-Specific Antibodies Therapy Business (2021-2026)
- 12.8.4 Pfizer Bi-Specific Antibodies Therapy Product Portfolio
- 12.8.5 Pfizer Recent Developments
- 12.9 Akeso, Inc.
- 12.9.1 Akeso, Inc. Company Information
- 12.9.2 Akeso, Inc. Business Overview
- 12.9.3 Akeso, Inc. Revenue in Bi-Specific Antibodies Therapy Business (2021-2026)
- 12.9.4 Akeso, Inc. Bi-Specific Antibodies Therapy Product Portfolio
- 12.9.5 Akeso, Inc. Recent Developments
- 12.10 Roche
- 12.10.1 Roche Company Information
- 12.10.2 Roche Business Overview
- 12.10.3 Roche Revenue in Bi-Specific Antibodies Therapy Business (2021-2026)
- 12.10.4 Roche Bi-Specific Antibodies Therapy Product Portfolio
- 12.10.5 Roche Recent Developments
- 12.11 Johnson & Johnson
- 12.11.1 Johnson & Johnson Company Information
- 12.11.2 Johnson & Johnson Business Overview
- 12.11.3 Johnson & Johnson Revenue in Bi-Specific Antibodies Therapy Business (2021-2026)
- 12.11.4 Johnson & Johnson Bi-Specific Antibodies Therapy Product Portfolio
- 12.11.5 Johnson & Johnson Recent Developments
- 12.12 Sanofi
- 12.12.1 Sanofi Company Information
- 12.12.2 Sanofi Business Overview
- 12.12.3 Sanofi Revenue in Bi-Specific Antibodies Therapy Business (2021-2026)
- 12.12.4 Sanofi Bi-Specific Antibodies Therapy Product Portfolio
- 12.12.5 Sanofi Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst